Loading
A phase 2 trial of FLOT, Bevacizumab, Cetuximab in colorectal cancer, run by Multitude Therapeutics Inc., now recruiting.
A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer is a phase 2 interventional study registered as NCT07474727 by Multitude Therapeutics Inc., with 180 participants planned, started 2026-04-29 and due to reach its primary completion in 2027-09-30. Interventions recorded: AMT-676, 5-FU, Leucovorin, Bevacizumab, Cetuximab. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), FOLFIRI (5-FU, leucovorin, irinotecan), CAPOX (capecitabine, oxaliplatin), Cetuximab.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Bevacizumab, Anti-angiogenic therapy.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), CAPOX (capecitabine, oxaliplatin), Bevacizumab, Anti-angiogenic therapy.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), Cetuximab, Bevacizumab, Anti-angiogenic therapy.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), FOLFIRI (5-FU, leucovorin, irinotecan), Bevacizumab, Colorectal cancer.
Shares Cetuximab, Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares CAPOX (capecitabine, oxaliplatin), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.